Unknown

Dataset Information

0

Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients.


ABSTRACT: Soft tissue sarcomas (STSs) are heterogeneous and aggressive malignancies with few effective therapies available. We have developed T cells expressing a vascular endothelial growth factor receptor 2 (VEGFR2)-specific chimeric antigen receptor (CAR) to establish a tumor angiogenesis-specific CAR-T cells impacting cancers (TACTICs) therapy. In this study, we optimized the manufacturing and transportation of mRNA-transfected anti-VEGFR2 CAR-T cells and collected information that allowed the extrapolation of the efficacy and safety potential of TACTICs therapy for STS patients. Although 5-methoxyuridines versus uridines did not improve CAR-mRNA stability in T cells, the utilization of CleanCap as a 5' cap-structure extended the CAR expression level, increasing VEGFR2-specific cytotoxicity. Furthermore, 4 °C preservation conditions did not affect the viability/cytotoxicity of CAR-T cells, contrarily to a freeze-thaw approach. Importantly, immunohistochemistry showed that most of the STS patients' specimens expressed VEGFR2, suggesting a great potential of our TACTICs approach. However, VEGFR2 expression was also detected in normal tissues, stressing the importance of the application of a strict monitoring schedule to detect (and respond to) the occurrence of adverse effects in clinics. Overall, our results support the development of a "first in humans" study to evaluate the potential of our TACTICs therapy as a new treatment option for STSs.

SUBMITTER: Fujiwara K 

PROVIDER: S-EPMC7598286 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients.

Fujiwara Kento K   Sasawatari Shigemi S   Nakai Sho S   Imaeda Keisuke K   Nagai Seina S   Matsuno Yoshihiro Y   Hatanaka Kanako K   Hatanaka Yutaka Y   Takenaka Satoshi S   Okada Naoki N  

Cancers 20200923 10


Soft tissue sarcomas (STSs) are heterogeneous and aggressive malignancies with few effective therapies available. We have developed T cells expressing a vascular endothelial growth factor receptor 2 (VEGFR2)-specific chimeric antigen receptor (CAR) to establish a tumor angiogenesis-specific CAR-T cells impacting cancers (TACTICs) therapy. In this study, we optimized the manufacturing and transportation of mRNA-transfected anti-VEGFR2 CAR-T cells and collected information that allowed the extrapo  ...[more]

Similar Datasets

| S-EPMC9974953 | biostudies-literature
| S-EPMC7050043 | biostudies-literature
| S-EPMC5716719 | biostudies-literature
| S-EPMC8293854 | biostudies-literature
| S-EPMC6691522 | biostudies-literature
| S-EPMC7174622 | biostudies-literature
| S-EPMC10670057 | biostudies-literature
| S-EPMC2393798 | biostudies-other
| S-EPMC5790336 | biostudies-literature
| S-EPMC3353406 | biostudies-other